Article: Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
AuthorsZheng, BJ1
Ng, MH1
He, LF2
Yao, X2
Chan, KW1
Yuen, KY1
Wen, YM2
KeywordsHepatitis B virus
Immune tolerance
Therapeutic vaccine
Issue Date2001
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2001, v. 19 n. 30, p. 4219-4225 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(01)00158-X
AbstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/S0264-410X(01)00158-X
ISI Accession Number IDWOS:000170090200017
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorZheng, BJ
dc.contributor.authorNg, MH
dc.contributor.authorHe, LF
dc.contributor.authorYao, X
dc.contributor.authorChan, KW
dc.contributor.authorYuen, KY
dc.contributor.authorWen, YM
dc.date.accessioned2012-05-29T06:11:53Z
dc.date.available2012-05-29T06:11:53Z
dc.date.issued2001
dc.description.abstractTherapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2001, v. 19 n. 30, p. 4219-4225 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S0264-410X(01)00158-X
dc.identifier.doihttp://dx.doi.org/10.1016/S0264-410X(01)00158-X
dc.identifier.epage4225
dc.identifier.isiWOS:000170090200017
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue30
dc.identifier.pmid11457548
dc.identifier.scopuseid_2-s2.0-0035919599
dc.identifier.spage4219
dc.identifier.urihttp://hdl.handle.net/10722/148265
dc.identifier.volume19
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.subject.meshAnimals
dc.subject.meshAntigen-Antibody Complex - Immunology
dc.subject.meshCytokines - Biosynthesis
dc.subject.meshDna, Recombinant - Immunology
dc.subject.meshHepatitis B - Therapy
dc.subject.meshHepatitis B Antibodies - Immunology
dc.subject.meshHepatitis B Surface Antigens - Blood - Immunology
dc.subject.meshHepatitis B Vaccines - Therapeutic Use
dc.subject.meshLiver - Pathology - Virology
dc.subject.meshMice
dc.subject.meshMice, Inbred C57bl
dc.subject.meshMice, Transgenic
dc.subject.meshT-Lymphocytes, Cytotoxic - Immunology
dc.subjectHepatitis B virus
dc.subjectImmune tolerance
dc.subjectTherapeutic vaccine
dc.titleTherapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. null